AI assistant
Sending…
NEOGENOMICS INC — Director's Dealing 2017
May 2, 2017
32227_dirs_2017-05-02_d0e0d5ea-5699-46d4-880e-88cd910d84b6.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NEOGENOMICS INC (NEO)
CIK: 0001077183
Period of Report: 2017-04-28
Reporting Person: ALBITAR MAHER (Chief Medical Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-04-28 | Stock Option (Right to Buy) | $7.52 | A | 200000 | Acquired | 2022-04-28 | Common Stock (200000) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 60692 | Indirect |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $7.15 | 2021-04-20 | Common Stock (200000) | 200000 | Direct |
Footnotes
F1: On April 20, 2016, Dr. Albitar was granted 200,000 stock options. These options vest ratably over the first three anniversary dates of the grant date.
F2: On April 28, 2017, Dr. Albitar was granted 200,000 stock options. The options vest ratably over the first three anniversary dates of the grant date.
More from NEOGENOMICS INC
Regulatory Filings
2026
May 22
Interim / Quarterly Report
2026
Apr 28
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Mar 4
Director's Dealing
2026
Mar 4
Director's Dealing
2026
Mar 4
Director's Dealing
2026
Mar 4
Director's Dealing
2026
Feb 24
Director's Dealing
2026
Feb 24
Director's Dealing
2026
Feb 24